10-KPeriod: FY2005

Cencora, Inc. Annual Report, Year Ended Sep 30, 2005

Filed December 9, 2005For Securities:COR

Summary

Cencora, Inc. (formerly AmerisourceBergen Corporation) reported fiscal year 2005 revenues of $50.0 billion, a 2% increase from the prior year, driven by growth in its Pharmaceutical Distribution segment. However, operating income saw a significant decline of 29% to $637 million, largely due to a decrease in gross profit margins, which fell to 3.96% from 4.44% in the previous year. This margin compression is attributed to changes in the pharmaceutical supply channel, including pressure to reduce price increases and a transition from manufacturer price-increase-dependent models to fee-for-service arrangements. The company is actively managing its cost structure through a significant distribution network consolidation plan, aiming to reduce facilities from 51 to the mid-20s by the end of fiscal year 2006. Additionally, Cencora is expanding its specialty pharmaceutical business, which has shown strong growth, and is investing in technology and services to enhance efficiency and patient outcomes. The company also announced a 100% increase in its quarterly dividend and a two-for-one stock split, signaling confidence in its future performance.

Key Highlights

  • 1Revenue increased by 2% to $50.0 billion in fiscal year 2005.
  • 2Operating income decreased by 29% to $637 million, reflecting margin pressures.
  • 3Gross profit margin declined to 3.96% from 4.44% due to industry-wide pricing and business model transition.
  • 4The company is undertaking a major distribution facility consolidation, reducing the network from 51 to approximately 28 facilities by the end of fiscal year 2006.
  • 5Acquisition of Trent Drugs (Wholesale) Ltd. in Canada marks an expansion into international markets.
  • 6The company's specialty pharmaceutical business continues to outperform the broader market.
  • 7Cencora declared a 100% increase in its quarterly dividend and announced a two-for-one stock split.

Frequently Asked Questions

Cencora (formerly AmerisourceBergen) is a leading pharmaceutical services company that distributes pharmaceuticals and provides related services to healthcare providers and manufacturers. In fiscal year 2005, the company reported revenues of $50 billion, a 2% increase, but experienced a 29% decrease in operating income due to declining gross margins.

The decline in gross profit margins is primarily attributed to a shift in the pharmaceutical industry away from manufacturer price increases as a driver of distributor profits. Cencora is transitioning to a fee-for-service model, and manufacturers are exerting more control over the supply chain through methods like Inventory Management Agreements (IMAs), which are impacting traditional margin structures.

Cencora is executing a significant integration plan to consolidate its distribution network, reducing the number of facilities. It is also focused on growing its specialty pharmaceutical business, expanding services to manufacturers and healthcare providers, and investing in technology to improve operational efficiency. The recent acquisition of Trent Drugs in Canada signifies an effort to broaden its geographic reach.

Cencora has actively managed its debt structure, refinancing notes to lower interest expenses and extend maturities. The company has a substantial share repurchase program in place and recently doubled its quarterly dividend, indicating management's confidence in its financial position and future cash flows.